Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in High-risk Non-muscular Invasive Bladder Cancer (NMIBC) With BCG Treatment Failure and HER2 Expression

NCT05957757 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT05957757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05957757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in High-risk Non-muscular Invasive Bladder Cancer (NMIBC) With BCG Treatment Failure and HER2 Expression
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 5, 2023
Completion date
June 8, 2026
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2, non-muscle invasive bladder cancer